SEC Form 4 · accession 0001179110-15-009587
Celldex Therapeutics, Inc. · CLDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harry Penner Jr.
Director
Period of report
Jun 10, 2015
Accepted (ET)
Jun 11, 2015 · 12:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000744218
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 10, 2015 | A | 6,500 | — | A | 21,916 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2,F3 | $25.41 | Jun 10, 2015 | A | 10,300 | A | — | Jun 10, 2025 | Common Stock | 10,300 | 10,300 | D |
Explanation of responses
- F1On June 10, 2015, the Company awarded 6,500 shares of the Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option and Incentive Plan, subject to time-based forfeiture restrictions.
- F2Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.
- F3Such option vests in four equal installments beginning September 10, 2015.